一个新型的针对大脑的纳米颗粒装载着比亚特拉基化物及其对阿尔茨海默病的保护作用
Qianmei Hu1,2,3,4, Candi Liu5, Jiawang Tan1,2,3,4
1Key Laboratory of Model Animals and Stem Cell Biology in Hunan Province, Hunan Normal University Health Science Center, Changsha 410013, China.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
概括
新型纳米颗粒携带甲基化物显示增强神经保护对抗阿尔茨海默病. 这些Tween-80修饰的纳米颗粒有效地准大脑,提高药物的疗效.
科学领域:
- 纳米技术纳米技术
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏病 (AD) 由于治疗药物的有限生物可用性和神经保护功效而构成重大挑战.
- 比亚特拉提洛利德显示出AD治疗的潜力,但需要改进的输送系统.
研究的目的:
- 开发一种新的Tween-80修饰的pullulan-chenodeoxycholic酸纳米粒子系统,用于增强传递biatractylolide.
- 评估开发的纳米粒子在阿尔茨海默病模型中的神经保护作用和脑向能力.
主要方法:
- 陈氧胆酸 (CDCA) 与普鲁兰结合,聚酸80 (Tween-80) 被吸附形成纳米粒子 (PUC).
- 纳米粒子以大小,形态和表面电荷为特征.
- 通过在SH-SY5Y和PC12细胞中使用Aβ25-35诱导的细胞毒性来评估体外神经保护.
- 在体内对大脑的准被评估使用实时成像.
主要成果:
- 鉴定证实均分散的球形纳米粒子,其水力动力直径为200nm.
- 与免费的比特拉提洛利德相比,带有比特拉提洛利德的纳米粒子 (BD-PUC) 显著提高了细胞存活率,并保留了形态.
- 在体内成像显示,BD-PUC纳米粒子在脑中有效积累.
结论:
- 开发的BD-PUC纳米颗粒与自由比特拉基化物相比,对Aβ25-35诱导的毒性具有优越的神经保护作用.
- Tween-80修改增强了纳米颗粒的脑准能力,为阿尔茨海默病治疗提供了一个有前途的策略.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678


